openPR Logo
Press release

Autoimmune Uveitis Market Set for Significant Growth in APAC by 2034 | Leading Companies: Tarsier Pharma, Eli Lilly, Oculis Pharma, Eyevensys, Priovant Therapeutics

06-21-2024 07:58 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

APAC Autoimmune Uveitis Market

APAC Autoimmune Uveitis Market

(Albany, USA) DelveInsight's "Autoimmune Uveitis - Market Size, Patient Pool Analysis, and Market Forecast APAC, 2034" report provides comprehensive insights into the historical and projected patient burden, treatable patient population, and notable market trends across the APAC region (India, China, South Korea, Taiwan, and Australia), highlighting distinctions from established markets.
The APAC Autoimmune Uveitis market report also offers insights into current treatment patterns, emerging prominent players, market shares of approved drugs, and peak share estimates for upcoming therapies. It covers historical and forecasted Autoimmune Uveitis market size, share, and trends in the Asia-Pacific region (India, China, South Korea, Taiwan, and Australia) during the study period (2020-2034). Additionally, the report examines recent treatment practices, therapy compliance, and accessibility, identifying unmet needs and evaluating market potential.

Autoimmune Uveitis Overview
Uveitis can result in temporary or permanent visual impairment and ocular problems that are not responsive to treatment since the condition involves recurrent intraocular inflammation.
Vision blurriness, photophobia, eye pain, floaters (floating spots), headaches, and injected conjunctiva are all typical signs of uveitis. It is usually asymptomatic in children. Uveitis can be classified according to the eye's anatomical parts affected by the disease or the underlying etiological cause. The etiological classification of uveitis includes infectious, noninfectious, and masquerade types of uveitis, among which noninfectious uveitis results in autoimmune uveitis.
Autoimmune uveitis is an inflammatory process of uveal components due to an autoimmune reaction to self-antigens or is caused by an innate inflammatory reaction secondary to an external stimulus. Eye inflammation can be the initial presentation in many autoimmune diseases (AD), manifesting as conjunctivitis, episcleritis, or scleritis. Diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are commonly associated with these manifestations. On the other hand, anterior uveitis typically appears as the initial manifestation of autoinflammatory diseases such as ankylosing spondylitis (AS).
There are no defined diagnostic or classification criteria for uveitis, so the diagnosis is based on a combination of clinical, instrumental, and laboratory tests. The eye examinations used to establish a uveitis diagnosis include an eye chart or visual acuity test, a funduscopic exam, an ocular pressure test, and a slit lamp exam.

Treatment for NIU aims to help relieve pain and discomfort in the eye, underlying cause, and reduce inflammation which can prevent permanent loss of vision or other complications. Corticosteroid eye drops are the first recommended treatment for noninfectious uveitis. Several corticosteroids (YUTIQ, OZURDEX, RETISERT, and others) are available in the market. Other treatment options such as 'conventional' systemic immunomodulators, and biologics can now be considered first-line agents in treating NIU, they are second or third options in most conditions.

The Autoimmune Uveitis Market in the APAC region, comprising countries such as India, China, South Korea, Taiwan, and Australia, is poised for significant growth and development. With the increasing recognition of autoimmune uveitis as a leading cause of vision impairment and blindness, there is a growing demand for effective treatments and management strategies to address this condition. Moreover, advancements in medical research and technology, along with the entry of pharmaceutical and biotech companies into the market, are expected to drive innovation and expand treatment options for patients with autoimmune uveitis. As a result, the autoimmune uveitis market in the APAC region is anticipated to witness transformative changes in the coming years, offering new opportunities for improved patient care and outcomes.

Get a Detailed Overview of the Evolving Autoimmune Uveitis Market Trends @
https://www.delveinsight.com/report-store/autoimmune-uveitis-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Autoimmune Uveitis Market
The Autoimmune Uveitis Market is poised for significant evolution, particularly within Asia-Pacific countries. This shift is underscored by the market outlook section of the report, which aims to enhance comprehension by delving into historical, present, and forecasted market projections. By examining the influence of both markets and emerging therapies, the report offers insights into the transformative forces at play. Furthermore, it conducts a thorough examination of the drivers, barriers, unmet needs, and emerging technologies within the Autoimmune Uveitis market landscape.

The report comprehensively outlines the market trends associated with every Autoimmune Uveitis drug currently available in the market and those in late-stage pipeline (i.e. Phase III stage) development. This thorough analysis encompasses various facets such as the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competitive landscape vis-à-vis other therapies, brand reputation, and their overall influence on the market dynamics. Furthermore, it incorporates insights from key opinion leaders, providing a holistic view of the market scenario.

Discover How the Autoimmune Uveitis Market Will Grow by 2034 @
https://www.delveinsight.com/report-store/autoimmune-uveitis-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Autoimmune Uveitis Epidemiology
The prevalence of Autoimmune Uveitis differs significantly across the APAC countries (India, China, South Korea, Taiwan, and Australia), influenced by a multitude of factors including genetics, demographics, lifestyle choices, and environmental elements. Within the report's epidemiology section, a comprehensive examination of patient burdens within each Asia-Pacific country is provided, encompassing historical, present, and projected trends. This analysis not only addresses the diagnosed and treated patient populations but also delves into sub-segments such as age-specific and gender-specific demographics, offering a nuanced understanding of the disease landscape within the region.

Get Key Insights Into the Evolving Autoimmune Uveitis Epidemiology Trends @
https://www.delveinsight.com/report-store/autoimmune-uveitis-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Autoimmune Uveitis Drugs Uptake and Pipeline Development Activities
Numerous leading pharmaceutical and biotechnology firms are actively engaged in developing therapies for Autoimmune Uveitis. This section of the Autoimmune Uveitis market report offers detailed insights into each therapy approved within the APAC countries, provided the therapy retains patent protection or market exclusivity in at least one APAC nation. Notably, off-label, generic, and biosimilar treatments are consolidated within the preceding treatment section of the report. Within this section, both marketed and late-stage (Phase III and Phase II) pipeline drugs are scrutinized, while early-phase drugs are presented in tabular format for clarity and accessibility.

Every Autoimmune Uveitis drug chapter within the report will encompass a comprehensive overview, comprising detailed descriptions, clinical trial evaluations, insights into research and development initiatives, as well as analyses of agreements and collaborations pertinent to each drug. Moreover, the chapters will delve into approval status, patent particulars, and a thorough examination of the advantages and disadvantages associated with each drug. Additionally, the report covers the latest updates and news pertaining to each product, ensuring a well-rounded understanding of the current landscape surrounding these therapies.

Explore More About Ongoing Pipeline Development Activities in the Autoimmune Uveitis Market @
https://www.delveinsight.com/sample-request/autoimmune-uveitis-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Autoimmune Uveitis Therapeutics Assessment
In the Asia-Pacific region, companies play a significant role in addressing the complexities of Autoimmune Uveitis. These companies are actively engaged in research and development efforts aimed at advancing novel therapies to combat this sight-threatening condition. Through strategic collaborations, partnerships, and investments, they seek to enhance treatment options and improve patient outcomes across diverse populations in countries such as India, China, South Korea, Taiwan, and Australia. Moreover, these companies contribute to raising awareness about Autoimmune Uveitis, supporting educational initiatives, and advocating for improved access to effective treatments. Their collective efforts are vital in addressing the unmet medical needs of patients and advancing the management of Autoimmune Uveitis in the Asia-Pacific region.

Leading Companies in the Autoimmune Uveitis Therapeutics Market Include
• Tarsier Pharma
• Eli Lilly and Company
• Oculis Pharma
• Eyevensys
• Priovant Therapeutics, Inc.
And Many Others

Learn More About the Emerging Therapies and key Companies in the Autoimmune Uveitis Therapeutics Market @
https://www.delveinsight.com/sample-request/autoimmune-uveitis-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content (TOC)
1. Key Insights
2. Autoimmune Uveitis Market Report Introduction
3. Autoimmune Uveitis Market Overview at a Glance
4. Autoimmune Uveitis Epidemiology and Market Methodology
5. Executive Summary
6. Key Events
7. Autoimmune Uveitis Disease Background and Overview
8. APAC Autoimmune Uveitis Patient Pool Analysis
9. APAC Autoimmune Uveitis Patient Journey
10. Marketed Autoimmune Uveitis Therapies
11. Emerging Autoimmune Uveitis Therapies
12. Autoimmune Uveitis APAC Market Analysis
13. Access and Reimbursement Scenario
14. KOL's Views on Autoimmune Uveitis Market
15. Autoimmune Uveitis SWOT Analysis
16. Autoimmune Uveitis Unmet Needs
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/autoimmune-uveitis-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Reports:
• 3d Cardiac Mapping System Market: https://www.delveinsight.com/report-store/3d-cardiac-mapping-system-market
• Absssi Market: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Acute Intermittent Porphyria Market: https://www.delveinsight.com/report-store/acute-intermittent-porphyria-market
• Acute Ischemic Stroke Ais Market: https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market
• Acute On Chronic Liver Failure Aclf Market: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market
• Adrenal Insufficiency Market: https://www.delveinsight.com/report-store/adrenal-crisis-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Age-related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Anemia In Ckd Market: https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/anti-cd274-pd-l1-antibody-pipeline-insight
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Athlete's Foot Market: https://www.delveinsight.com/report-store/athletes-foot-market
• Biliary Atresia Market: https://www.delveinsight.com/report-store/biliary-atresia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Car T Therapy For Acute Lymphoblastic Leukemia All Market: https://www.delveinsight.com/report-store/car-t-cell-therapy-for-acute-lymphoblastic-leukemia

Contact Info:
Ankit Nigam
Manager (Marketing & Branding)
Email: anigam@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Autoimmune Uveitis Market Set for Significant Growth in APAC by 2034 | Leading Companies: Tarsier Pharma, Eli Lilly, Oculis Pharma, Eyevensys, Priovant Therapeutics here

News-ID: 3547706 • Views:

More Releases from DelveInsight Business Research

Molybdenum cofactor deficiency type A Treatment Market 2034: FDA Approvals, Clinical trials, Therapies, Prevalence and Companies by DelveInsight
Molybdenum cofactor deficiency type A Treatment Market 2034: FDA Approvals, Clin …
(Albany, USA) DelveInsight's "Molybdenum cofactor deficiency type A Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Molybdenum cofactor deficiency type A, historical and forecasted epidemiology as well as the Molybdenum cofactor deficiency type A market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Molybdenum cofactor deficiency type A market outlook, drug uptake, treatment
Stuttering Treatment Market 2034: FDA Approvals, Clinical trials, Therapies, Pre …
(Albany, USA) DelveInsight's "Stuttering Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Stuttering, historical and forecasted epidemiology as well as the Stuttering market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Stuttering market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Stuttering pipeline products will significantly
Tenosynovial Giant Cell Tumors Treatment Market 2034: FDA Approvals, Clinical trials, Therapies, Prevalence and Companies by DelveInsight | Daiichi Sankyo, Deciphera Pharmaceuticals, Abbisko Therapeutics, AmMax Bio, SynOx Therapeutics
Tenosynovial Giant Cell Tumors Treatment Market 2034: FDA Approvals, Clinical tr …
(Albany, USA) DelveInsight's "Tenosynovial Giant Cell Tumors Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Tenosynovial Giant Cell Tumors, historical and forecasted epidemiology as well as the Tenosynovial Giant Cell Tumors market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Tenosynovial Giant Cell Tumors market outlook, drug uptake, treatment scenario and epidemiology trends,
Hidradenitis Suppurativa Treatment Market 2034: FDA Approvals, Clinical trials, Therapies, Prevalence and Companies by DelveInsight | AbbVie, Novartis, UCB Biopharma, Eli Lilly, Institut Pasteur, MoonLake Immunotherapeutics, ACELYRIN, More
Hidradenitis Suppurativa Treatment Market 2034: FDA Approvals, Clinical trials, …
(Albany, USA) DelveInsight's "Hidradenitis Suppurativa Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Hidradenitis Suppurativa, historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Hidradenitis Suppurativa market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hidradenitis Suppurativa Market Forecast https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr Some of the

All 5 Releases


More Releases for Uveitis

Japan Industry Statistics of Uveitis Treatment
Global Uveitis Treatment Market: Overview Uveitis, an autoimmune eye disease, is considered rare for just around 38 in 100,000 people are afflicted by it. Because of this, it is often overlooked. Patients afflicted by uveitis are often referred to an expert after much delay on account of less awareness about the eye malady. This delays timely diagnosis and results in irreversible damage to various ocular structures. Read Report Overview: https://www.transparencymarketresearch.com/uveitis-treatment-market.html As per Cochrane,
Uveitis Treatment Market Analysis of Top industry Scenario
Global Uveitis Treatment Market report it provides a vital recent industry data which covers in general market situation along with future scenario for industry around the Globe. It also consists of major data along with forecasts of a global market along with clear presentation of diagrams (charts and tables). According to a new report published by Allied Market Research, titled, "Uveitis Treatment Market by Drug Class (Anti-inflammatory, Antimicrobial Drugs, Immunotherapy &
Uveitis Treatment Market: Global Market Of Uveitis Disease Is Estimated To Reach …
Uveitis Treatment Market Precision Business Insights (PBI) in its report titled “Global Uveitis Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2017 and Forecast 2018-2027” assesses the market performance over 2018-2027. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period. Uveitis is swelling of the middle layer of the eye,
Uveitis Therapeutic and Disease Pipeline Review H1
Summary Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or
Anterior Uveitis Market: An Industry Case Study
Uveitis is the inflammation of the uveal region of the eye, most commonly by an infection. Uvea is a group of pigmented and non pigmented tissues lying in the middle among the three layers that make the eye. Uvea again consists of three layers: iris, cilliary body and the choroid. The uvea is also known as the uveal tract in some medical circles, this tract is necessary for the nutrition
Uveitis Treatment Market By Indication (Anterior uveitis, Intermediate uveitis, …
Uveitis is a combined condition of inflammation and swelling of the eyes. Uvea comprises of three parts Iris, ciliary body (small ring shape muscles behind iris and choroid), and choroid (it is the layer of tissue between retina and sclera), which decides eye color and helps eye in focusing and absorbing light. Uveitis can be caused by eye problems, autoimmune disease, HIV, multiple sclerosis, reactive arthritis, Kawasaki disease tuberculosis, and